{"id":390578,"date":"2018-09-28T00:00:00","date_gmt":"2018-09-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0009-2018-biopharma-breast-cancer-current-treatment-physician-insights-us-2018\/"},"modified":"2026-04-24T05:25:12","modified_gmt":"2026-04-24T05:25:12","slug":"cutron0009-2018-biopharma-breast-cancer-current-treatment-physician-insights-us-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutron0009-2018-biopharma-breast-cancer-current-treatment-physician-insights-us-2018\/","title":{"rendered":"Breast Cancer | Current Treatment: Physician Insights | US | 2018"},"content":{"rendered":"<p>Hormone receptor (<abbr title=\"hormone receptor\">HR<\/abbr>)-positive\/<abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative breast cancer is the most prevalent breast cancer subtype. Treatment decisions are influenced by disease stage, genetic test score, menopausal status, resectability, site of metastasis, and prior treatment received. The recent approval of three <abbr title=\"cyclin-dependent kinase 4\">CDK4<\/abbr>\/6 inhibitors in the metastatic setting in the United States (Pfizer\u2019s Ibrance, Novartis\u2019s Kisqali, and Eli Lilly\u2019s Verzenio) has altered physicians\u2019 prescribing habits and created new dynamics in treatment sequencing. Furthermore, the approval of AstraZeneca\u2019s <abbr title=\"poly ADP (adenosine diphosphate)-ribose polymerase\">PARP<\/abbr> inhibitor Lynparza for metastatic g<em>BRCA<\/em>-positive, <abbr title=\"human epidermal growth factor receptor-2\">HER2<\/abbr>-negative breast cancer patients has given an additional treatment option to physicians for this subgroup of patients who are also <abbr title=\"hormone receptor\">HR<\/abbr>-positive.<\/p>\n","protected":false},"template":"","class_list":["post-390578","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-breast-cancer","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390578","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390578\/revisions"}],"predecessor-version":[{"id":393702,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390578\/revisions\/393702"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390578"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}